Track topics on Twitter Track topics that are important to you
Ondansetron was associated with a low risk for birth defects in neonates who were exposed during the first trimester of pregnancy, and the incidence of cardiac malformations may be increased slightly....
First-trimester use seems safe, although data are still limited.
Drug delivery specialist Midatech (LON:MPTH) will commercially launch Zuplenz, its anti-vomiting drug for chemo and radiotherapy patients, in the US this week. Midatech acquired the treatment from G...
A new study suggests that the drug ondansetron, sold as Zofran, does not increase the risk of birth defects when taken for severe nausea and vomiting during pregnancy.
The source of a potential deadly blood infection in more than 50 South American cancer patients has now been identified by researchers. All of the patients infected with S. Kiliense received ondansetr...
Women suffering from extreme morning sickness often take Zofran (ondansetron) to combat their debilitating nausea and vomiting. However, two studies have found that the drug may increase risk of heart...
Midatech Pharma (NASDAQ: MTP) has the full commercial launch of Zuplenz (ondansetron) in the US. The drug is an oral soluble film to prevent post-operative, chemotherapy and radiation-induced nausea a...
Ondansetron improves the success of oral rehydration in children with gastroenteritis. In postoperative adults, ondansetron has been shown to prolong the corrected QT (QTc). The aim of the study was t...
Therapy for moderate to severe acute food protein induced enterocolitis syndrome (FPIES) typically consists of intravenous fluids and corticosteroids (traditional therapy). Ondansetron has been sugges...
Ondansetron is known to cause QT interval prolongation, but this effect and clinical significance has not been prospectively studied in adult emergency department (ED) patients. The primary objective ...